ClinicalTrials.gg
Active, not recruitingNCT04951219Updated May 27, 2026

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A Phase 3 interventional study of Resmetirom in Non-Alcoholic Fatty Liver Disease, sponsored by Madrigal Pharmaceuticals, Inc.. Active, not recruiting at 76 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
19th of 460
810 · median 56
Started
2021
with 56 others
Phase 3
29 of 547
7 open now
Primary completion
2027-03
later than 40 of 92 live
Registered
405th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 19th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 29 in phase 3, reaches primary completion later than 40 of the 92 other live ones, and was the 405th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease

Keywords

  • NAFLD
  • NASH
  • Hyperlipidemia
  • Resmetirom
  • Thyroid hormone receptor beta
  • Hepatic
  • Fibrosis
  • NASH resolution
  • Thyroid hormone receptor agonist
  • Cardiovascular
  • Dyslipidemia
  • Fatty liver disease
  • Nonalcoholic steatohepatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients who completed MAESTRO-NAFLD-1, completed the Week 52 visit, and completed the Week 56 visit within 90 days of the Extension Day 1 visit, and are willing to participate in MAESTRO-NAFLD-OLE and provide written .
  • For patients who screen failed MAESTRO-NASH, must provide written informed consent for MAESTRO-NAFLD-OLE and must have screened and met all eligibility requirements for MAESTRO-NASH within 90 days of the Extension Day 1 visit for MAESTRO-NAFLD-OLE and have a liver that is ineligible for MAESTRO-NASH within 6 months of the Extension Day 1 visit. Eligible liver biopsy for MAESTRO-NAFLD-OLE must have one of the following results:

    • NAS = 3, steatosis 1, ballooning 1, inflammation 1, OR NAS = 3, ballooning 0, with F1B, F2 or F3
    • NAS ≥ 4, at least 1 in all NAS components, F1A or F1C, PRO-C3 ≤ 14 (NASH, but ineligible for MAESTRO-NASH)
    • Compensated NASH cirrhosis based on biopsy at screening of MAESTRO-NASH and baseline of MAESTRO-NAFLD-OLE, including -A (score 5-6), MELD \<12, albumin ≥3.2, and \<2
  • For patients who screen failed from MAESTRO-NASH OUTCOMES and de novo patients, must have documented CP-A/B (score \<8) NASH cirrhosis (including minimal decompensation) and MELD \<15 unless MELD >=15 based on non-cirrhotic parameters. MAESTRO-NASH OUTCOMES screen failures must have screened and met all eligibility requirements for MAESTRO-NASH OUTCOMES within 90 days of the Extension Day 1 visit for MAESTRO-NAFLD-OLE .

Exclusion criteria

Exclusion Criteria:

  • A history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Extension Day 1.
  • Diagnosis of hepatocellular carcinoma or other carcinomas that may prevent participation in the Extension study.
  • Chronic liver diseases
  • Has an active disease
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    Double-blind 80 mg Daily

    For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 80 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52

    Drug: Resmetirom

  • Experimental
    Double-blind 100 mg Daily

    For patients assigned to double-blind treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, double-blind resmetirom 100 mg for first 12 weeks followed by open-label resmetirom 100 mg for weeks 12-52

    Drug: Resmetirom

  • Experimental
    Open-label

    For patients assigned to open-label treatment and who completed Week 52 and 56 of MAESTRO-NAFLD-1, open-label resmetirom at same dose as MGL-3196-14 for an additional 52 weeks. NASH cirrhosis patients may receive open-label resmetirom for up to an additional 66 months (ie, 52 weeks in MGL-3196-14 and up to 66 months in MGL-3196-18).

    Drug: Resmetirom

  • Experimental
    Open-Label 80 mg

    For patients with NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 80 mg for up to 66 months.

    Drug: Resmetirom

  • Experimental
    Open Label 100 mg

    For patients without NASH cirrhosis who were screen failures from MGL-3196-11, open-label resmetirom 100 mg for 52 weeks

    Drug: Resmetirom

  • Experimental
    Open-Label 40 mg

    For NASH cirrhosis patients who enter MGL-3196-18 directly or were screen failures from MGL-3196-19, open-label resmetirom 40 mg for up to 66 months.

    Drug: Resmetirom

Interventions

06

What researchers measure

Primary outcomes

  1. The effect of once daily, oral administration of resmetirom on the incidence of adverse events.

    Time frame: 52 weeks

Secondary outcomes

  1. Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline

    Time frame: 16 weeks

  2. Percent change in the hepatic fat fraction as determined by MRI-PDFF from baseline

    Time frame: 52 weeks

  3. Percent change in LDL-C from baseline

    Time frame: 28 weeks

07

Study locations

76 sites
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Arizona Liver Health - Chandler
    Chandler, Arizona 85224, United States
  • East Valley Family Physicians
    Chandler, Arizona 85224, United States
  • The Institute For Liver Health - Glendale
    Glendale, Arizona 85306, United States
  • The Institute For Liver Health - Tucson
    Tucson, Arizona 85711, United States
  • Adobe Gastroenterology
    Tucson, Arizona 85712, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • Ruane Clinical Research Group
    Los Angeles, California 90036, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • National Research Institute - Los Angeles
    Los Angeles, California 90057, United States
  • National Research Institute - Panorama City
    Panorama City, California 91402, United States
  • San Fernando Valley Health Institute
    West Hills, California 91307, United States
  • South Denver Gastroenterology - Swedish Medical Center Office
    Englewood, Colorado 80113, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Covenant Research
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research, Hallandale Beach (MD Clinical)
    Hallandale, Florida 33009, United States
  • Floridian Clinical Research
    Hialeah, Florida 33016, United States
  • Nature Coast Clinical Research - Inverness
    Inverness, Florida 34452, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Orlando Research Center
    Orlando, Florida 32806, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Covenant Research
    Sarasota, Florida 34240, United States
  • The Villages Research Center
    The Villages, Florida 32162, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Chicago Research Center
    Chicago, Illinois 60602, United States
  • Northwestern Memorial Physicians Group
    Chicago, Illinois 60611, United States
  • Iowa Diabetes Research
    West Des Moines, Iowa 50265, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • Kansas Medical Clinic - Gastroenterology
    Topeka, Kansas 66606, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Rovia Clinical Research
    Bastrop, Louisiana 71220, United States
  • Digestive Health Center of Louisiana
    Baton Rouge, Louisiana 70809, United States
  • Tandem Clinical Research - New Orleans Area Site
    Marrero, Louisiana 70072, United States
  • Clinical Trials of America
    West Monroe, Louisiana 71291, United States
  • Gastrointestinal Associates & Endoscopy Center - Flowood
    Flowood, Mississippi 39232, United States
  • Southern Therapy and Advanced Research
    Jackson, Mississippi 39216, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Henderson Research Center
    Henderson, Nevada 89052, United States
  • Clarity Clinical Research
    East Syracuse, New York 13057, United States
  • Velocity Clinical Research
    East Syracuse, New York 13057, United States
  • Mount Sinai Health System
    New York, New York 10029, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cumberland Research Associates
    Fayetteville, North Carolina 28304, United States
  • Lucas Research
    Moorehead City, North Carolina 28557, United States
  • Diabetes and Endocrinology Consultants
    Morehead City, North Carolina 28557, United States
  • Aventiv Research Columbus
    Columbus, Ohio 43213, United States
  • Awasty Research Network
    Marion, Ohio 43302, United States
  • Innovative Clinical Research
    Clarksville, Tennessee 37040, United States
  • Gastro One - Germantown Office - Wolf Park Drive
    Germantown, Tennessee 38138, United States
  • Pinnacle Clinical Research - Austin
    Austin, Texas 78746, United States
  • The Liver Institute At Methodist Dallas
    Dallas, Texas 75203, United States
  • Dallas Research Center
    Dallas, Texas 75234, United States
  • Liver Center of Texas
    Dallas, Texas 75234, United States
  • South Texas Research Institute
    Edinburg, Texas 78539, United States
  • Texas Digestive Disease Consultants
    Fort Worth, Texas 76104, United States
  • Liver Associates of Texas
    Houston, Texas 77030, United States
  • Doctor's Hospital at Renaissance
    McAllen, Texas 78504, United States
  • Plano Research Center
    Plano, Texas 75093, United States
  • Texas Liver Institute/American Research Corporation
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
  • San Antonio Research Center
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - San Marcos
    San Marcos, Texas 78666, United States
  • Impact Research Institute
    Waco, Texas 76710, United States
  • Texas Digestive Disease Consultants - Bay Area Houston Endoscopy Center
    Webster, Texas 77598, United States
  • Wasatch Peak Family Practice
    Layton, Utah 84041, United States
  • Salt Lake City Research Center
    Murray, Utah 84123, United States
  • Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • National Clinical Research - Richmond
    Richmond, Virginia 23294, United States
  • Virginia Commonwealth University School of Medicine
    Richmond, Virginia 23298, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
  • Fundacion de Investigacion de Diego
    San Juan, Puerto Rico
08

References and documents

Publications

  • Harrison SA, Ratziu V, Anstee QM, Noureddin M, Sanyal AJ, Schattenberg JM, Bedossa P, Bashir MR, Schneider D, Taub R, Bansal M, Kowdley KV, Younossi ZM, Loomba R. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2024 Jan;59(1):51-63. doi: 10.1111/apt.17734. Epub 2023 Oct 2. PubMed 37786277 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Mar 2027, 68 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jul 6, 2021
StartActual
Jul 9, 2021
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04951219
Responsible party
Sponsor
First posted
Jul 6, 2021
Start date
Jul 9, 2021
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 27, 2026

Study contacts

Tom Hare, MD
study director · Madrigal Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion